| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/07/2002 | WO2002018608A2 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018576A2 Compositions and methods relating to lung specific genes |
| 03/07/2002 | WO2002018572A2 Membrane penetrating peptides and uses thereof |
| 03/07/2002 | WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | WO2002018450A1 New cross-linked derivatives of hyaluronic acid |
| 03/07/2002 | WO2002018448A2 Percarboxylated polysaccharides, and a process for their preparation |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018438A1 Modified proteins, isolated novel peptides, and uses thereof |
| 03/07/2002 | WO2002018437A2 Cyclic peptides having melanocortin-4 receptor agonist activity |
| 03/07/2002 | WO2002018422A1 Amino acid substitution mutants of interleukin 13 |
| 03/07/2002 | WO2002018404A2 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018389A2 Thienopyrimidine |
| 03/07/2002 | WO2002018385A1 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES |
| 03/07/2002 | WO2002018384A1 Process for the preparation of vitronectin receptor antagonists |
| 03/07/2002 | WO2002018383A2 Aza heterocyclic derivatives and their therapeutic use |
| 03/07/2002 | WO2002018382A1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 03/07/2002 | WO2002018380A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| 03/07/2002 | WO2002018378A1 Pyrrolidine derivatives and their use as chymase inhibitor |
| 03/07/2002 | WO2002018377A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | WO2002018374A1 Substituted pyrimidines as selective cyclooxygenase-2 inhibitors |
| 03/07/2002 | WO2002018369A2 Peptidomimetic protease inhibitors |
| 03/07/2002 | WO2002018368A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| 03/07/2002 | WO2002018367A1 Tetrahydrobenzindole derivatives capable of binding to 5-ht7 receptor and metabolically stable |
| 03/07/2002 | WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | WO2002018355A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| 03/07/2002 | WO2002018353A2 Oxazolidinone chemotherapeutic agents |
| 03/07/2002 | WO2002018350A1 Grk inhibitor |
| 03/07/2002 | WO2002018348A2 Quinazoline derivatives as alpha-1 adrenergic antagonists |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018341A2 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002018335A1 Cyclic amine derivatives |
| 03/07/2002 | WO2002018333A1 Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors |
| 03/07/2002 | WO2002018330A1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| 03/07/2002 | WO2002018327A2 Guanidinobenzamides as mc4-r agonists |
| 03/07/2002 | WO2002018324A2 Immunoregulatory compounds, derivatives thereof and their use |
| 03/07/2002 | WO2002018310A1 Method of obtaining a hydroxytyrosol-rich composition from vegetation water |
| 03/07/2002 | WO2002017965A1 Medicinal compositions |
| 03/07/2002 | WO2002017963A2 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 03/07/2002 | WO2002017954A1 Antiparkinsonism drugs |
| 03/07/2002 | WO2002017949A2 Novel functions for dp214 |
| 03/07/2002 | WO2002017948A2 Control of crop pests and animal parasites through direct neuronal uptake |
| 03/07/2002 | WO2002017938A1 Use of extracts of the cassia alata plant |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017924A1 Method of treatment |
| 03/07/2002 | WO2002017923A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 03/07/2002 | WO2002017919A2 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017906A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | WO2002017899A2 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/07/2002 | WO2002017894A2 Pharmaceutical formulation of salmeterol and fluticasone propionate |
| 03/07/2002 | WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 03/07/2002 | WO2002017890A2 Treatment of arthritis and compositions therefore containing a n-acylated-2-glucosamine derivative |
| 03/07/2002 | WO2002017878A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | WO2002017858A2 Role of fosb in bone formation |
| 03/07/2002 | WO2002017857A2 Methods and compositions for inhibiting angiogenesis |
| 03/07/2002 | WO2002017713A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001089457A3 Thrombopoietin mimetics |
| 03/07/2002 | WO2001080811A3 Mmp-2 propeptide for use as antiangiogenic or antitumor agent |
| 03/07/2002 | WO2001079269A3 Lipid binding protein 4 |
| 03/07/2002 | WO2001078649A3 Pharmaceutical curative compound |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001064678A3 Inhibitors of hepatitis c virus ns3 protease |
| 03/07/2002 | WO2001064226A3 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 03/07/2002 | WO2001064194A3 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 03/07/2002 | WO2001062765A3 Small molecule modulators of g protein-coupled receptor six |
| 03/07/2002 | WO2001060983A3 Treatment for bone disorders |
| 03/07/2002 | WO2001060407A3 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis |
| 03/07/2002 | WO2001059130A3 Proteins producing an altered immunogenic response and methods of making and using the same |
| 03/07/2002 | WO2001058949A3 Heterologous polypeptide of the tnf family |
| 03/07/2002 | WO2001058471A3 Novel amino acid and peptide inhibitors of staphylococcus virulence |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001056556A3 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001055131A3 Prodigiosin-derivatives as neoplastic and anti-viral agents |
| 03/07/2002 | WO2001053493A3 Human kinase protein and polynucleotides encoding the same |
| 03/07/2002 | WO2001046405A3 Modulation of pax-2 for controlled apoptosis or survival of cells |
| 03/07/2002 | WO2001046231A3 Polynucleotides and polypeptides encoded thereby |
| 03/07/2002 | WO2001043761A3 Methods for treating and preventing damage to mucosal tissue |
| 03/07/2002 | WO2001043692A3 SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 03/07/2002 | WO2001042285A3 Extracellular matrix and cell adhesion proteins as well as genes encoding them |
| 03/07/2002 | WO2001036686A3 Genomic polymorphism for predicting therapeutic response |
| 03/07/2002 | WO2001023377A3 Polymorphic salt |
| 03/07/2002 | WO2001021163A3 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/07/2002 | WO2001015673A3 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/07/2002 | WO2001001974A3 Naaladase inhibitors in anxiety and memory disorders |
| 03/07/2002 | WO2000071571A8 Fap-activated anti-tumor compounds |
| 03/07/2002 | US20020028973 Bactericides, antioxidants, and antiinflammatory agents |
| 03/07/2002 | US20020028953 Process for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid |
| 03/07/2002 | US20020028951 Process for preparing eprosartan |
| 03/07/2002 | US20020028949 Synthesis of (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one |
| 03/07/2002 | US20020028943 For lowering serum lipid, cholesterol and/or triglyceride levels; treating atherosclerosis |
| 03/07/2002 | US20020028934 Process for preparing benzoxazin-4-one polymer conjugates |
| 03/07/2002 | US20020028933 Thioamide derivatives |